SuvasiniLakshmananMD

Physician

Dr. Lakshmanan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 Hawkins Dr Dept of
Iowa City, IA 52242
Phone+1 319-384-8001

Fax+1 319-353-6343

UMass Chan Medical SchoolResidency, Internal Medicine, 2013 - 2016
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 2012

PubMed

258 citations
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Matthew J. Budoff, Deepak L. Bhatt, April Kinninger, Suvasini Lakshmanan, Joseph B. Muhlestein
European Heart Journal. 2020-10-21
4 citations
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coron...
Divya Birudaraju, Lavanya Cherukuri, April Kinninger, S. Dahal, Suvasini Lakshmanan
Journal of Diabetes and Its Complications. 2021-03-01
52 citations
Major Global Coronary Artery Calcium Guidelines.
Ilana S Golub, Orly G Termeie, Stephanie Kristo, Lucia P Schroeder, Suvasini Lakshmanan
JACC. Cardiovascular Imaging. 2023-01-01

Cleerly to Present Innovative Research on Age and Sex-Specific Coronary Artery Disease at AHA Scientific Sessions 2024November 13th, 2024
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific SessionMay 4th, 2021